Status:
TERMINATED
Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Lead Sponsor:
Cartesian Therapeutics
Conditions:
Myeloma Multiple
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following in...
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older at the time of enrollment
- High-risk multiple myeloma patients who complete pre-transplant induction treatment anti- myeloma drug combination (minimum 2 drugs).
Exclusion
- Patients who are pregnant or lactating.
- Patients who have any active and uncontrolled infection. No blood cultures are necessary unless clinically indicated.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2022
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04816526
Start Date
December 1 2021
End Date
November 3 2022
Last Update
October 8 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Irvine
Orange, California, United States, 92868
2
Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States, 37203